| Date | Title | Description |
| 17.09.2026 | INDIGO Biosciences Launches IL-6R Reporter Assay to Support Inflammation, Immunology, and Oncology Drug Discovery | IL-6R Inhibition Assay Plot
IL-6R Activation Assay Plot
New Cell-Based Assay Supports Functional Characterization of IL-6 Receptor Signaling in Drug Discovery Research STATE COLLEGE, PA, UNITED STATES, September 17, 2026 /EINPresswire.com/ ... |
| 11.06.2026 | INDIGO Biosciences Launches Bradykinin Reporter Assays for Inflammation, Pain, and Vascular Disease Drug Discovery | B1R, Activation Assay
B2R, Activation Assay
New Cell-Based Assays Support Functional Screening of Bradykinin Receptor Signaling Across High-Value GPCR Research Programs STATE COLLEGE, PA, UNITED STATES, June 11, 2026 /EINPresswire.com/ -- I... |
| 07.05.2026 | INDIGO Biosciences Expands Reporter Assay Capabilities with New Transrepression Assay Services | Plot of Human GR Mediated Repression of NF-kB Transcriptional Activity
New service offering enables GR/NF-κB transrepression studies to support deeper mechanism-of-action insight in drug discovery programs STATE COLLEGE, PA, UNITED STATES, ... |
| 14.04.2026 | INDIGO Biosciences Launches GPR39 Reporter Assay for Metabolic, Gastrointestinal, and Inflammatory Disease Research | GPR39 Activation Assay Graph
New Cell-Based Assay Supports Drug Discovery Targeting Glucose Homeostasis, Barrier Integrity, and Tissue Repair STATE COLLEGE, PA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- INDIGO Biosciences, a leadi... |
| 31.03.2026 | INDIGO Biosciences Achieves Record Revenue in 2025 | Performance driven by core drug discovery, continued adoption in environmental toxicology, and launch of new assays and a stable reporter cell line platform. STATE COLLEGE, PA, UNITED STATES, March 31, 2026 /EINPresswire.com/ -- INDIGO Bios... |
| 19.03.2026 | INDIGO Biosciences Launches CHRM1 (Cholinergic Receptor, Muscarinic 1) Reporter Assays for Cognitive Drug Discovery | Activation Dose Response Curve of CHRM1
New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE COLLEGE, PA, UNITED STATES, March 19, 2026 /EINPresswire.com/ -- INDIGO Biosciences... |
| 15.01.2026 | INDIGO Biosciences Launches AMY1 and AMY3 Receptor Reporter Assays for Metabolic and Neuroendocrine Research | AMY1R, Activation Assay
AMY3R, Activation Assay
New Cell-Based Assays Support Drug Discovery Across the Amylin Receptor Family STATE COLLEGE, PA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- INDIGO Biosciences, a premier provider o... |
| 15.09.2025 | INDIGO Biosciences Launches Melanocortin Receptor Reporter Assay Family | Activation of MC2R utilizing INDIGO's MC2R assay kit.
Suite of MCR Assays Enables Targeted Drug Discovery Across MC1R, MC2R, MC3R, MC4R, and MC5R Receptors STATE COLLEGE, PA, UNITED STATES, September 15, 2025 /EINPresswire.com/ -- INDIGO Bi... |
| 29.07.2025 | INDIGO Biosciences Expands Alternative Species Portfolio with Six New Receptor Assays for Cross-Species Drug Screening | Pig PGR Agonist Graph
Pig Assay Joins Industry-Leading Catalog, Supporting Translational and Comparative Research STATE COLLEGE, PA, UNITED STATES, July 29, 2025 /EINPresswire.com/ -- INDIGO Biosciences, a global leader in cell-based assay ... |
| 24.04.2025 | INDIGO Biosciences Celebrates 20 Years of Scientific Excellence | Two decades of assay development, scientific support, and global impact in life sciences STATE COLLEGE, PA, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- INDIGO Biosciences, a leading provider of cell-based reporter assays and in vitr... |
| 23.08.2024 | INDIGO Biosciences Releases Luciferase Reporter Assays for Arginine Vasopressin Receptors AVPR1A, AVPR1B, and AVPR2 | AVPR1A Activation Assay
AVPR1B Activation Assay
AVPR2 Activation Assay
New Assays Empower Research into Cardiovascular Health, Neuropsychiatric Disorders, and Water Balance Regulation STATE COLLEGE, PENNSYLVANIA, UNITED STATES, August 23, 2... |
| 02.07.2024 | INDIGO Biosciences Releases Cell-Based Luciferase Reporter Assay for Gastric Inhibitory Polypeptide Receptor (GIPR) | GIPR Activation Assay
GIPR Inhibition Assay
A New Sensitive, Time-Saving Assay for Preclinical Research of Metabolic Disorders and Cardiovascular Diseases STATE COLLEGE, PENNSYLVANIA, UNITED STATES, July 2, 2024 /EINPresswire.com/ -- INDIGO... |
| 04.06.2024 | INDIGO Biosciences Introduces Cell-Based Luciferase Reporter Assay for Human c-MET / Hepatocyte Growth Factor Receptor | Activation of c-MET
Inhibition of C-MET
A New Sensitive, Time-Saving Assay for Preclinical Research of Cancer, Fibrosis, and Inflammatory Diseases STATE COLLEGE, PENNSYLVANIA, UNITED STATES, June 4, 2024 /EINPresswire.com/ -- INDIGO Bioscie... |
| 18.04.2024 | INDIGO Biosciences Introduces Cell-Based Luciferase Reporter Assay for Hepatocyte Nuclear Factor 4 Alpha (HNF4α) | Agonist dose-response of Human HNF4a.
Inverse-Agonist dose-response of Human HNF4a.
A New Sensitive, Time-Saving Assay for Preclinical Research of Metabolic Regulation and Disease Pathogenesis STATE COLLEGE, PENNSYLVANIA, UNITED STATES, Apr... |
| 20.03.2024 | INDIGO Biosciences Releases Cell-Based Luciferase Reporter Assay for the Human Oxytocin Receptor | Performance of INDIGO Biosciences' OXTR assay in activation mode.
Performance of INDIGO Biosciences' OXTR assay in inhibition mode.
A New Sensitive, Time-Saving Assay for Preclinical Research of Reproductive Health, Mental Health Disorders,... |
| 21.02.2024 | INDIGO Biosciences Releases a Family of Cell-Based Reporter Assays for the Adrenergic Receptors | Activation of ADRA1A
Activation of ADRA1B
Activation of ADRA1D
New Assays Include ADRA1A, ADRA1B, ADRA1D, ADRB1, and ADRB2 for Preclinical Research of Heart Failure, Hypertension, Obesity, and Respiratory Conditions STATE COLLEGE, PA, USA, ... |
| 17.07.2023 | INDIGO Biosciences Releases New Assay for Preclinical Research of Cancer and Autoimmune Diseases | A New Assay Cell-Based Luciferase Reporter Assay has been developed for GM-CSFR. STATE COLLEGE, PA, UNITED STATES, July 17, 2023/EINPresswire.com/ -- INDIGO Biosciences, a leading provider of cell-based luciferase reporter assays, is please... |
| 31.05.2023 | INDIGO Biosciences Releases New Family of Cell-Based Assays for Environmental Monitoring and Toxicology Applications | New Assays Provide a Screening Tool for Endocrine Disrupting Chemicals STATE COLLEGE, PA, UNITED STATES, May 31, 2023/EINPresswire.com/ -- Today INDIGO Biosciences released a new family of cell-based luciferase reporter assays specifically ... |
| 22.02.2023 | INDIGO Biosciences Announces Record Year for 2022 | Cell-Based Assay Solutions Provider Books Another Year of Record Growth STATE COLLEGE, PA, UNITED STATES, February 22, 2023 /EINPresswire.com/ -- INDIGO Biosciences, Inc. (INDIGO), best known for its portfolio of cell-based luciferase repor... |
| 05.12.2022 | Environmental Monitoring: Evaluating Cellular Response Pathways in Complex Mixtures, Upcoming Webinar Hosted by Xtalks | Is there a better way to determine what pathways are impacted by individual contaminants as well as complex mixtures? The answer is yes!
TORONTO (PRWEB) December 05, 2022
Cell-based in vitro bioassays have been used in environmental monitor... |
| 29.11.2022 | INDIGO Biosciences Announces New Assay for Human G Protein-Coupled Bile Acid Receptor 1 (GPBAR1; TGR5) | Because bile acids modulate signaling pathways for several nuclear receptors, this GPCR assay pairs well with INDIGO’s existing assays for Farnesoid X Receptor (FXR), Pregnane X Receptor (PXR), and Vitamin D Receptor (VDR).
STATE COLLEGE, P... |
| 15.11.2022 | INDIGO Biosciences Receives Approval from California Water Boards for Use of Its Bioassays in Recycled Water Monitoring | We look forward to developing additional bioassays that can help water boards and regulators everywhere monitor for contaminants that pose potential environmental and health risks.
STATE COLLEGE, Pa. (PRWEB) November 15, 2022
INDIGO Bioscie... |
| 28.09.2022 | INDIGO Biosciences Expands Assays for Cancer Research with Human Tumor Protein P53 | INDIGO’s new P53 assay is valuable for researchers who want to understand how a potential compound affects cellular stress and toxicology pathways along with any potential off-target effects such as drug-drug interactions.
STATE COLLEGE, Pa... |
| 29.08.2022 | INDIGO Biosciences Announces New Assay for Human Activator Protein 1 (AP-1) | INDIGO’s new AP-1 assay is a fantastic tool that provides researchers with valuable information about whether their compounds of interest act as activators or inhibitors of AP-1.
STATE COLLEGE, Pa. (PRWEB) August 29, 2022
INDIGO Biosciences... |
| 26.08.2022 | Nuclear Receptors and Cancer Research: Current Trends and Applications, Upcoming Webinar Hosted by Xtalks | In this webinar, learn about cutting edge research from distinguished professors from Penn State University as they talk about the role of specific nuclear receptors in cancer.
TORONTO (PRWEB) August 26, 2022
Nuclear receptors have long bee... |
| 11.07.2022 | INDIGO Biosciences Develops Two New Progesterone Receptor Ortholog Assays | With the addition of these new products, we can offer researchers more than forty different ortholog assays across six different species including monkey, dog, mouse, rat, zebrafish, and now—rabbit.
STATE COLLEGE, Pa. (PRWEB) July 11, 2022
... |
| 17.05.2022 | INDIGO Biosciences Offers New Assay to Test Development and Oncology Therapeutics | “The addition of this assay allows researchers in oncology and development insight into potential interactions with this receptor in the earliest stages of their research.”
STATE COLLEGE, Pa. (PRWEB) May 17, 2022
INDIGO Biosciences, the rec... |
| 12.04.2022 | Nuclear Receptors and Drug-Drug Interactions: How to Better Understand Potential Toxicity, Upcoming Webinar Hosted by Xtalks | Register for this webinar to learn about various drug screening assays that are available for identifying potential DDI in vitro.
TORONTO (PRWEB) April 12, 2022
Drug-drug interactions (DDI) resulting in adverse outcomes cause approximately ... |
| 23.02.2022 | INDIGO Biosciences Inc. Announces A Record Revenue for 2021 | INDIGO Biosciences Logo “INDIGO provides superior products and service to the industries we serve. With the trust of our customers, the INDIGO team members delivered a breakout year in 2021. The Company is poised for significant growth, and... |
| 18.01.2022 | INDIGO Biosciences Releases New Luciferase Detection Reagent | INDIGO Biosciences Logo “We are excited to offer INDIGlo, our new firefly luciferase detection reagent, to our customers,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “It is an ideal, detection reagent for both low- and... |
| 17.11.2021 | Biomonitoring: Relevance of Bioassays in Water Treatment, Upcoming Webinar Hosted by Xtalks | The aim of this presentation is to identify bioassays commonly applied to water extracts and provide guidance on assay selection and subsequent interpretation.
TORONTO (PRWEB) November 17, 2021
Human-impacted surface, ground and drinking wa... |
| 19.10.2021 | INDIGO Biosciences Expands Portfolio for Preclinical Metabolic Disease Research | "The addition of our FGFR/β-Klotho assay further strengthens our commitment to provide vital data in the earliest stages of discovery, expanding opportunities for research into therapeutics for metabolic diseases.” - Dr. Jack Vanden He... |
| 31.08.2021 | INDIGO Biosciences Expands Portfolio for Preclinical Development and Oncology Research | FGFR plays a key role in the development and function of most of the body’s vital organs, and understanding how even small mutations can lead to disease onset and progression is crucial for development of potential screening and treatment m... |
| 13.07.2021 | INDIGO Biosciences Expands Portfolio to Include Cannabinoid Type 1 Receptor | CB1R represents an exciting expansion for our team in both technology and our understanding of the role cannabinoid receptors play in the critical disease states in which our customers work, including oncology and neurological disorders.
ST... |
| 20.04.2021 | INDIGO Biosciences Expands Preclinical Portfolio for Anemia and Oncology Research | “The addition of EPOR to INDIGO’s portfolio expands our understanding of red blood cell production as it relates to both beneficial and harmful downstream effects in other areas of disease state development.”
STATE COLLEGE, Pa. (PRWEB) Apri... |
| 16.03.2021 | INDIGO Biosciences Expands Autoimmune-Focused Preclinical Testing Portfolio | "The addition of NFAT to our portfolio expands opportunities for autoimmune and oncology researchers to get the critical interaction and activation data they need, before entering costly clinical trials."
STATE COLLEGE, Pa. (PRWEB... |
| 05.01.2021 | INDIGO Biosciences Expands Oncology-Focused Preclinical Testing Portfolio | INDIGO is committed to consistently offering discovery scientists new ways to move their research forward faster, and these oncology-focused offerings aim to help researchers make critical decisions with confidence.
STATE COLLEGE, Pa. (PRWE... |
| 25.01.2018 | The Union League’s angel fund pumped $1 million into 5 startups | Angel investing group Broad Street Angels, based out of the tony Union League of Philadelphia, came out of stealth mode right around this time last year and set out to find early stage startups to back.
A year later, after reviewing around ... |
| 15.01.2018 | EXCLUSIVE: Biotech Dominates THRIVE Top 50 in AgTech List | Biotech and predictive analytics startups dominate the Salinas, CA-based THRIVE AgTech’s Top 50 list of agtech companies shaping the future of agriculture for 2018.
The largest technology category on last year’s list, “big data analytics,” ... |
| 08.08.2016 | Indigo Biosciences Raises $500K in Series B Financing | Indigo Biosciences, a State College, PA-based provider of both products and services focused on nuclear receptors, raised $500k in Series B financing.
The round – which has an overall goal of $1.5m – was led by the Life Sciences Greenhouse ... |
| 03.08.2016 | INDIGO Biosciences Raises $500K in Series B Funding | INDIGO Biosciences announced the completion of a $500,000 Series B financing round on June 28, 2016. The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and AGSM, a private equity investment firm from Pittsburgh, Pennsylvania led t... |
| 03.08.2016 | INDIGO Biosciences Raises $500K in Series B Funding | INDIGO Biosciences announced the completion of a $500,000 Series B financing round on June 28, 2016. The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and AGSM, a private equity investment firm from Pittsburgh, Pennsylvania led t... |
